Advanced Search

Medicare Compliance & Reimbursement

Pharmaceuticals:

DRUG REBATES REMAIN UNDER OIG'S MICROSCOPE

Published on Sun Oct 26, 2003

Feds goad states on Medicaid drug rebate accounting.  The Medicaid drug rebate program has become a compliance flashpoint for pharmaceutical manufacturers - and the HHS Office of Inspector General wants to make sure state Medicaid agencies have their act together when it comes to balancing the books on this hot-button issue. Over the course of the year, the watchdog agency has examined drug rebate programs in dozens of states, calling health departments to the mat if their collection procedures aren't up to snuff. In the latest round of audits, the OIG takes the measure of programs in five states - Kentucky, Georgia, South Carolina, Tennessee and Florida - all of which, the agency says, need to get their houses in order. Problems ranged from lack of appropriate accounting records and ineffective collections procedures to the failure to pursue interest as appropriate. To see the reports, numbered A-04-03-06006, A-04-03-06010, A-04-03-06011, A-04-03-06012 and A-04-03-06016, go to http://oig.hhs.gov/oas/oas/cms.html.
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Medicare Compliance & Reimbursement

View All